A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1617 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-29

Study Completion Date

2020-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combination (FDC) or free combo) or LAMA treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA

NCT02546349

COPD

UNKNOWN PHASE4

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

NCT01937390

Pulmonary Disease, Chronic Obstructive

COMPLETED

A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination

NCT03858348

COPD COPD Exacerbation

COMPLETED

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

NCT01794780

COPD

COMPLETED PHASE4

Comparative Effectiveness of COPD Treatments

NCT03376295

Pulmonary Disease, Chronic Obstructive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with Tiotropium and Olodaterol

Tiotropium + Olodaterol

Intervention Type DRUG

Spiolto®

Subjects treated with other LABA/LAMA therapy

Other LABA/LAMA

Intervention Type DRUG

tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium

Subjects treated with LAMA therapy

LAMA

Intervention Type DRUG

aclidinium bromide, glycopyrronium, tiotropium, umeclidinium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tiotropium + Olodaterol

Spiolto®

Intervention Type DRUG

Other LABA/LAMA

tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium

Intervention Type DRUG

LAMA

aclidinium bromide, glycopyrronium, tiotropium, umeclidinium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients who fulfil ALL the following criteria are included.

1. Patients who diagnosed with COPD who were prescribed with LABA/LABA (FDC or free combo) as a new initiation or switching from other therapy (i.e., single/dual/triple), or newly receiving LAMA treatment for 3 months at least prior to 30 June 2018
2. Male or female patients ≥ 40 years of age

Exclusion Criteria

1\. Patients who meet the following criterion are not included.

* Patients with documented diagnosis of bronchial asthma, asthma-COPD overlap syndrome (ACOS), bronchiectasis, cystic fibrosis, or lung cancer

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No